Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia: A novel therapeutic strategy to boost chemotherapy response and overcome resistance
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia : A novel therapeutic strategy to boost chemotherapy response and overcome resistance. / Theilgaard-Mønch, Kim.
I: J Cell Immunol, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Theilgaard-Mønch, K 2024, 'Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia: A novel therapeutic strategy to boost chemotherapy response and overcome resistance', J Cell Immunol.
APA
Theilgaard-Mønch, K. (2024). Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia: A novel therapeutic strategy to boost chemotherapy response and overcome resistance. Manuskript afsendt til publicering.
Vancouver
Theilgaard-Mønch K. Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia: A novel therapeutic strategy to boost chemotherapy response and overcome resistance. J Cell Immunol. 2024.
Author
Bibtex
@article{f5839ec0ba684ab5a9458c9070584ec6,
title = "Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia: A novel therapeutic strategy to boost chemotherapy response and overcome resistance",
author = "Kim Theilgaard-M{\o}nch",
year = "2024",
language = "English",
journal = "J Cell Immunol",
}
RIS
TY - JOUR
T1 - Therapeutic inhibition of DNA-Damage Response and PI3K/AKT signaling in Acute Myleoid Leukemia
T2 - A novel therapeutic strategy to boost chemotherapy response and overcome resistance
AU - Theilgaard-Mønch, Kim
PY - 2024
Y1 - 2024
M3 - Journal article
JO - J Cell Immunol
JF - J Cell Immunol
ER -
ID: 290193502